Ultragenyx Pharmaceutical Inc
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Capital expenditures decreased by 14% from FY24 to FY25.
Current Price
$24.77
+0.32%GoodMoat Value
$28.14
13.6% undervaluedUltragenyx Pharmaceutical Inc (RARE) Stock Chart
RARE Interactive Stock Chart
Interactive stock chart for Ultragenyx Pharmaceutical Inc (RARE) with candlestick and line chart views. Analyze price action across multiple timeframes: 5 days, 1 week, 1 month, 3 months, 6 months, 1 year, 5 years, and full history.
Current price: $24.77. 52-week high: $41.44. 52-week low: $18.50. 50-day moving average: $22.55. 200-day moving average: $27.72.
Technical analysis indicators include Volume, SMA 20, SMA 50, SMA 200, EMA 20, and RSI. Toggle between candlestick and line chart styles. Overlay multiple moving averages to identify support and resistance levels, trend direction, and momentum signals for RARE. Use the chart alongside GoodMoat's fundamental analysis tools for a complete picture of Ultragenyx Pharmaceutical Inc's investment potential.